NewGenIvf Group (NIVF) to Release Quarterly Earnings on Thursday

NewGenIvf Group (NASDAQ:NIVF) is expected to be issuing its resultson Thursday, July 30th. Analysts expect NewGenIvf Group to post earnings of $556.20 per share and revenue of $2.8720 million for the quarter.

NewGenIvf Group (NASDAQ:NIVF) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($861.72) EPS for the quarter. The company had revenue of $1.42 million for the quarter. On average, analysts expect NewGenIvf Group to post $14 EPS for the current fiscal year and $28 EPS for the next fiscal year.

NewGenIvf Group Price Performance

Shares of NASDAQ NIVF opened at $1.27 on Thursday. The company has a quick ratio of 2.98, a current ratio of 3.12 and a debt-to-equity ratio of 0.16. NewGenIvf Group has a 1-year low of $1.19 and a 1-year high of $568.53. The company has a fifty day moving average price of $1.98 and a 200 day moving average price of $7.27.

Insider Activity

In other news, major shareholder Financial Lp Hrt sold 28,439 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $2.40, for a total value of $68,253.60. Following the completion of the sale, the insider owned 18,187 shares of the company’s stock, valued at approximately $43,648.80. This represents a 60.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 31.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

NIVF has been the topic of a number of research reports. Weiss Ratings restated a “sell (d)” rating on shares of NewGenIvf Group in a report on Monday, April 27th. Wall Street Zen upgraded NewGenIvf Group to a “hold” rating in a report on Saturday, July 4th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, NewGenIvf Group currently has a consensus rating of “Sell”.

About NewGenIvf Group

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.